KKR completed its $5.89 billion acquisition of Integer Holdings on August 29, the largest healthcare private equity transaction of the quarter and the firm's second medical device platform build in sixteen months. The deal values Integer at 13.2x trailing EBITDA and gives KKR control of $1.6 billion in annual revenue across cardiac rhythm management and neuromodulation manufacturing.
Healthcare represented 31% of global private equity deal value in August, up from 19% in July, while total PE volumes declined 22% month-over-month to $47 billion across 143 transactions. The Integer acquisition alone accounted for 12.5% of August's global PE activity. KKR's healthcare portfolio now holds $38 billion in assets under management, positioning the firm as the second-largest healthcare-focused PE player after Blackstone.
The timing reflects structural advantages in medical technology M&A that persist despite rising financing costs. Integer's customer concentration—68% of revenue from top-ten medtech OEMs including Medtronic and Boston Scientific—provides immediate cross-sell visibility for KKR's existing portfolio companies. The company operates fourteen FDA-registered facilities with 5,200 employees, creating operational synergies with KKR's Avantor life sciences platform acquired in 2022 for $6.4 billion. Contract manufacturing margins in cardiac devices average 24-26% EBITDA, roughly 400 basis points above general industrial manufacturing.
August's healthcare deal activity diverged sharply from broader PE trends. Technology buyouts fell to $8.3 billion from $14.7 billion in July, while industrials dropped 38% to $6.1 billion. Three factors drove healthcare's relative strength: regulatory approval timelines now average eleven months for medical device acquisitions versus eighteen months for tech deals requiring antitrust review; debt markets remain open for healthcare at 7.2% weighted average cost versus 8.4% for software LBOs; and strategic buyers paid an average 1.8x premium to PE bids in contested healthcare auctions this quarter.
Allocators should monitor three follow-on events through Q4 2024. First, KKR plans to merge Integer's neuromodulation unit with its portfolio company Relievant Medsystems by October, creating a $340 million revenue platform in spinal nerve stimulation. Second, Integer's manufacturing capacity in Mexico—42% of production volume—positions the asset for nearshoring tailwinds as medtech OEMs accelerate supply chain regionalization; Abbott and Stryker have announced $890 million in combined Mexico capex for 2025. Third, KKR's healthcare deal pipeline includes $12 billion in signed LOIs for Q4 closes, suggesting the sector's August share may represent a floor rather than a peak.
Integer's EBITDA grew 11% annually from 2020 through 2023, faster than the 7% median for contract manufacturers, and KKR paid a 14% discount to the 15.3x average for medtech services deals this year.